Table 3.
Comparison of vaccine-associated SAT cases by the vaccine type
| Variables* | Inactivated COVID-19 vaccine–associated group (n = 10) | mRNA COVID-19 vaccine–associated group (n = 6) | p-value# |
|---|---|---|---|
| N (%) | 10 (62.5) | 6 (37.5) | - |
| Age, median (range), years | 47.5 (32.0–71.0) | 44.0 (32.0–67.0) | 0.36 |
| Female gender, n (%) | 7 (70.0) | 5 (83.3) | 0.55 |
| Post-vaccination symptom onset time, median (range), days | 8.0 (4.0–20.0) | 5.0 (2.0–15.0) | 0.23 |
| Time to diagnosis, median (range), days | 32.5 (19.0–80.0) | 29.0 (18.0–90.0) | 0.79 |
| Overt hyperthyroidism at diagnosis, n (%) | 6 (60.0) | 5 (83.3) | 0.59 |
| The laboratory tests at diagnosis | |||
| TSH, median (range), mIU/L | 0.02 (0.01–1.50) | 0.01 (0.01–0.14) | 0.63 |
| fT4, median (range), pmol/L | 29.41 (12.10–88.04) | 26.73 (16.99–53.54) | 0.79 |
| WBC, median (range), 103/ mm3 | 8.55 (5.27–12.09) | 8.90 (5.88–16.70) | 0.87 |
| ESR, median (range), mm/h | 37.5 (19.0–66.0) | 43.5 (23.0–66.0) | 0.96 |
| CRP, median (range), mg/L | 38.5 (5.7–224.0) | 22.3 (13.0–136.0) | 0.91 |
| Disease involvement, n (%)1.00 | |||
| Unilateral | 5 (50.0) | 3 (50.0) | - |
| Bilateral | 5 (50.0) | 3 (50.0) | - |
| Thyroid volume at diagnosis, median (range), cm3 | 20.08 (7.49–33.81) | 27.18 (12.17–38.05) | 0.26 |
| Treatment modality, n (%) | 0.70 | ||
| Ibuprofen | 6 (60.0) | 3 (50.0) | - |
| Methylprednisolon | 4 (40.0) | 3 (50.0) | - |
| Follow-up time, median (range), days | 42.5 (31.0–59.0) | 34.0 (20.0–93.0) | 0.31 |
| Euthyroidism at follow-up, n (%) | 7 (70.0) | 4 (66.0) | 0.60 |
CRP C-reactive protein, ESR erythrocyte sedimentation rate, fT4 free thyroxine, NSAIDs non-steroidal anti-inflammatory drugs, TSH thyroid-stimulating hormone, WBC white blood cells*Non-normally distributed data are reported using median (min–max)#In the comparison of continuous variables, p-values were calculated with the Mann–Whitney U test. In the comparison of categorical variables, p-values were calculated with the χ.2 test